FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma By Ogkologos - January 31, 2025 496 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CK-301-101 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Retifanlimab February 26, 2024 Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma November 29, 2022 EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp August 13, 2020 Experts Urge to Remove Care Inequalities for Adolescents and Young Adults... April 8, 2021 Load more HOT NEWS Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of... Research with integrity – the importance of communication New on NCI’s Websites for September 2021 This Breast Cancer Patient Is Using Boudoir Photography to Reclaim Her...
